BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Credit Suisse maintains outperform on Sun Pharmaceutical Industries
Credit Suisse has maintained "outperform" rating on Sun Pharma with a target price of Rs 880. Weak India sales growth is affecting both Sun Pharma and Ranbaxy. Sun Pharma's India business margins improved but its growth is a concern.